CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: Analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma

British Journal of Haematology

Volumn 146, Issue 1, 2009, Pages 34-43

  Takeshita, Akihiro ^a,b   Shinjo, Kaori ^a   Yamakage, Nozomi ^b   Ono, Takaaki ^a   Hirano, Isao ^a   Matsui, Hirotaka ^a   Shigeno, Kazuyuki ^a   Nakamura, Satoki ^a   Tobita, Tadasu ^c   Maekawa, Masato ^b   Ohnishi, Kazunori ^a   Sugimoto, Yoshikazu ^d   Kiyoi, Hitoshi ^e   Naoe, Tomoki ^e   Ohno, Ryuzo ^f  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b AT Laboratory   (Japan)

^c Yaizu Shimin Hospital   (Japan)

^d KEIO UNIVERSITY   (Japan)

^e NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Calicheamicin; CD22; CMC 544; Monoclonal antibody; P glycoprotein

Indexed keywords

CD22 ANTIGEN; GLYCOPROTEIN P; INOTUZUMAB OZOGAMICIN;

ARTICLE; B LYMPHOCYTE; CELL COUNT; CELL DEATH; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MORPHOLOGY; MULTIDRUG RESISTANCE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD22; ANTINEOPLASTIC AGENTS; CELL COUNT; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CYCLOSPORINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JURKAT CELLS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, NON-HODGKIN; P-GLYCOPROTEIN; QUINOLINES; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 66949176946     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.07701.x     Document Type: Article

References (34)

1. Andreadis, C., Gimotty, P.A., Wahl, P., Hammond, R., Houldsworth, J., Schuster, S.J. Rebbeck, T.R. (2007) Members of the glutathione and ABC-transporter families are associated with clinical outcome in patients with diffuse large B-cell lymphoma. Blood, 109, 3409 3416. (Pubitemid 46572530)
2. Auer, R.L., Gribben, J. Cotter, F.E. (2007) Emerging therapy for chronic lymphocytic leukaemia. British Journal of Haematology, 139, 635 644. (Pubitemid 350115738)
3. Bonavida, B. (2007) Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene, 26, 3629 3636. (Pubitemid 46842700)
4. Cheson, B.D. (2006) Monoclonal antibody therapy for B-cell malignancies. Seminars in Oncology, 33, S2 S14.
5. Coiffier, B. (2007) Rituximab therapy in malignant lymphoma. Oncogene, 26, 3603 3613. (Pubitemid 46844778)
6. DiJoseph, J.F., Amelino, D.C., Boghhaert, E.R., Khandke, K., Dougher, M.M., Sridharan, L., Kunz, A., Hamann, P.R., Gorovits, B., Udata, C., Moran, J.K., Popplewell, A.G., Stephens, S., Frost, P. Damle, N.K. (2004) Antibody-tageted chemotherapy with CMC-544: a CD22-tageted imunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood, 103, 1807 1814. (Pubitemid 38268977)
7. DiJoseph, J.F., Dougher, M.M., Kalyandrug, L.B., Armellino, D.C., Boghaert, E.R., Hamann, P.R. Damle, N.K. (2006) Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma. Clinical Cancer Research, 12, 242 249. (Pubitemid 43166200)
8. DiJoseph, J.F., Dougher, M.M., Armellino, D.C., Evans, D.Y. Damale, N.K. (2007) Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia, 21, 2240 2245. (Pubitemid 350011695)
9. Faderl, S., Coutré, S., Byrd, J.C., Dearden, C., Denes, A., Dyer, M.J., Gregory, S.A., Gribben, J.G., Hillmen, P., Keating, M., Rosen, S., Venugopal, P. Rai, K. (2005) The evolving role of alemtuzumab in management of patients with CLL. Leukemia, 19, 2147 2152. (Pubitemid 41741608)
10. Fanale, M.A. Younes, A. (2007) Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. Drugs, 67, 333 350. (Pubitemid 46425549)
11. Friedenberg, W.R., Spencer, S.K., Musser, C., Hogan, T.F., Rodvold, K.A., Rushing, D.A., Mazza, J.J., Tewksbury, D.A. Marx, J.J. (1999) Multi-drug resistance in chronic lymphocytic leukemia. Leukemia & Lymphoma, 34, 171 178. (Pubitemid 29248673)
12. Goemans, B.F., Zwaan, C.M., Vijverberg, S.J., Loonen, A.H., Creutzig, U., Hählen, K., Reinhardt, D., Gibson, B.E., Cloos, J. Kaspers, G.J. (2008) Large interindividual differences in cellular sensitivity to calicheamicin may influence gemtuzumab ozogamicin response in acute myeloid leukemia. Leukemia, 22, 2284 2285.
13. Hiddemann, W., Buske, C., Dreyling, M., Weigert, O., Lenz, G. Unterhalt, M. (2006) Current management of follicular lymphomas. British Journal of Haematology, 136, 191 202. (Pubitemid 46020746)
14. Karasawa, S., Araki, T., Yamamoto-Hino, M. Miyawaki, A. (2003) A green-emitting fluorescent protein from Galaxeidae coral and its monomeric version for use in fluorescent labeling. Journal of Biological Chemistry, 278, 34167 34171. (Pubitemid 37553258)
15. Kartner, N., Everrnden-Porelle, D., Bradley, G. Ling, V. (1985) Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature, 316, 820 823. (Pubitemid 15003741)
16. Larson, R.A., Sievers, E.L., Stadtmauer, E.A., Löwenberg, B., Estey, E.H., Dombret, H., Theobald, M., Voliotis, D., Bennett, J.M., Richie, M., Leopold, L.H., Berger, M.S., Sherman, M.L., Loken, M.R., van Dongen, J.J., Bernstein, I.D. Appelbaum, F.R. (2005) Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer, 104, 1442 1452. (Pubitemid 41356159)
17. Matsui, H., Takeshita, A., Naito, K., Shinjo, K., Shigeno, K., Maekawa, M., Yamakawa, Y., Tanimoto, M., Kobayashi, M., Ohnishi, K. Ohno, R. (2002) Reduced effect of gemtuzumab ozogamicin (CMC-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers. Leukemia, 16, 813 819. (Pubitemid 34537552)
18. Matthews, C., Catherwood, M.A., Larkin, A.M., Clynes, M., Morris, T.C. Alexander, H.D. (2006) MDR-1, but not MDR-3 gene expression, is associated with unmutated IgVH genes and poor prognosis chromosomal aberrations in chronic lymphocytic leukemia. Leukemia & lymphoma, 47, 2308 2313. (Pubitemid 44768423)
19. Merlin, J.L., Guerci, A.P., Marchal, S., Bour, C., Colosetti, P., Kataki, A. Guerci, O. (1998) Influence of SDZ-PSC833 on daunorubicin intracellular accumulation in bone marrow specimens from patients with acute myeloid leukaemia. British Journal of Haematology, 103, 480 487. (Pubitemid 28522457)
20. Montserrat, E., Moreno, C., Esteve, J., Urbano-Ispizua, A., Giné, E. Bosch, F. (2006) How I treat refractory CLL. Blood, 107, 1276 1283. (Pubitemid 43242359)
21. Müller, M.R., Lennartz, K., Nowrousian, M.R., Dux, R., Tsuruo, T., Rajewsky, M.F. Seeber, S. (1994) Improved flow-cytometric detection of low P-glycoprotein expression in leukaemic blasts by histogram subtraction analysis. Cytometry, 15, 64 72.
22. Naito, K., Takeshita, A., Shigeno, K., Nakamura, S., Fujisawa, S., Shijo, K., Yoshida, H., Ohnishi, K., Mori, M., Terakawa, S. Ohno, R. (2000) Caliceamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab ozogamicin, CMC676) shows cytocydal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines. Leukemia, 14, 1436 1443. (Pubitemid 30601355)
23. Nakanishi, O., Baba, M., Saito, A., Yamashita, T., Sato, W., Abe, H., Fukazawa, N., Suzuki, T., Sato, S., Naito, M. Tsuruo, T. (1997) Potentiation of the antitumor activity by a novel quinoline compound, MS-209, in multidrug-resistant solid tumor cell lines. Oncology Research, 9, 61 69. (Pubitemid 127825886)
24. Ohsawa, M., Ikura, Y., Fukushima, H., Shirai, N., Sugama, Y., Suekane, T., Hirayama, M., Hino, M. Ueda, M. (2005) Immunohistochemical expression of multidrug resistance proteins as a predictor of poor response to chemotherapy and prognosis in patients with nodal diffuse large B-cell lymphoma. Oncology, 68, 422 431. (Pubitemid 41160973)
25. Sugimoto, Y., Sato, S., Tsukahara, S., Suzuki, M., Okochi, E., Gottesman, M.M., Pastan, I. Tsuruo, T. (1997) Coexpression of a multidrug resistance gene (MDR1) and herpes simplex virus thymidine kinase gene in a bicistronic retroviral vector Ha-MDR-IRES-TK allows selective killing of MDR1-transduced human tumors transplanted in nude mice. Cancer Gene Therapy, 4, 51 58. (Pubitemid 127672236)
26. Svoboda-Beusan, I., Kusec, R., Bendelja, K., Tudoric-Ghemo, I., Jaksic, B., Pejsa, V., Rabatic, S. Vitale, B. (2000) The relevance of multidrug resistance-associated P-glycoprotein expression in the treatment response of B-cell chronic lymphocytic leukemia. Haematologica, 85, 1261 1267. (Pubitemid 32063695)
27. Takeshita, A., Shinjo, K., Naito, K., Matsui, H., Shigeno, K., Nakamura, S., Horii, T., Maekawa, M., Kitamura, K., Naoe, T., Ohnishi, K. Ohno, R. (2003) P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) are induced by arsenic trioxide (As(2)O(3)), but are not the main mechanism of As(2)O(3)-resistance in acute promyelocytic leukemia cells. Leukemia, 17, 648 650. (Pubitemid 36395665)
28. Takeshita, A., Shinjo, K., Naito, K., Matsui, H., Sahara, N., Shigeno, K., Horii, T., Shirai, N., Maekawa, M., Ohnishi, K., Naoe, T. Ohno, R. (2005) Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells. Leukemia, 19, 1306 1311. (Pubitemid 41136319)
29. Taksin, A.L., Legrand, O., Raffoux, E., de Revel, T., Thomas, X., Contentin, N., Bouabdallah, R., Pautas, C., Turlure, P., Reman, O., Gardin, C., Varet, B., de Botton, S., Pousset, F., Farhat, H., Chevret, S., Dombret, H. Castaigne, S. (2007) High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. Leukemia, 21, 66 71. (Pubitemid 44921836)
30. Tedder, T.F., Tuscano, J., Sato, S. Kehrl, J.H. (1997) CD22, a B lymphocyte-specific adhesion molecule that regurates antigen receptor signaling. Annual Review of Immunology, 15, 481 504. (Pubitemid 27169290)
31. Tsimberidou, A., Estey, E., Cortes, J., Thomas, D., Faderl, S., Verstovsek, S., Garcia-Manero, G., Keating, M., Albitar, M., O'Brien, S., Kantarjian, H. Giles, F. (2003) Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. Cancer, 97, 1481 1487. (Pubitemid 36297778)
32. Walter, R.B., Gooley, T.A., van der Velden, V.H., Loken, M.R., van Dongen, J.J., Flowers, D.A., Bernstein, I.D. Appelbaum, F.R. (2007) CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood, 109, 4168 4170. (Pubitemid 46743379)
33. Yajima, T., Yagihashi, A., Kameshima, H., Kobayashi, D., Furuya, D., Hirata, K. Watanabe, N. (1998) Quantitative reverse transcription-PCR assay of the RNA component of human telomerase using the TaqMan fluorogenic detection system. Clinical Chemistry, 44, 2441 2445. (Pubitemid 28565655)
34. Zein, N., Sinha, A.M., McGahren, W.J. Ellestad, G.A. (1988) Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science, 240, 1198 1201. (Pubitemid 18143936)